GMED vs VRTX
Globus Medical vs Vertex Pharmaceuticals — AI-powered side-by-side comparison
GMED
Globus Medical
70
Buy
VS
VRTX
Vertex Pharmaceuticals
67
Buy
| Metric | GMED | VRTX |
|---|
| AI Score |
70
|
67
|
| Price |
$82.34
|
$496.21
|
| P/E Ratio |
20.74×
|
28.64×
|
| ROE |
11.8%
|
21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.5%
|
86.0%
|
| Debt / Equity |
0.02×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
64.2
|
66.6
|
| Beta |
0.954
|
0.292
|
| Expected Upside |
+1.8%
|
+2.3%
|
AI Committee View
Current Innellis committee reasoning for GMED versus VRTX.
GMED leads by 3 points.
GMED scores 70/100 (Buy) versus VRTX at 67/100 (Buy).
GMED Committee View
100% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is 4 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- EPS growing 221.2% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Lower Highs / Lower Lows structure confirms bearish price action.
VRTX Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock. The main limiting factor is p/e of 28.3 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 28.3 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- Price trading above the upper Bollinger Band -- stretched — Technical